Med Check: Psilocybin for OCD, Nuplazid Vote, and More
Psychiatric News August 1, 2022 DOI: 10.1176/appi.pn.2022.08.8.2 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Placebo Atomoxetine Obstructive sleep apnea Anesthesia Clinical trial |
| Key points | The FDA has granted fast track designation to AD109, an investigational oral combination of atomoxetine and aroxybutynin, for treating obstructive sleep apnea, Apnimed announced. Fast track is meant to expedite development and review of drugs for serious conditions with unmet medical need. No clinical results are reported. |
Abstract
AD109 Fast Tracked for Obstructive Sleep ApneaThe U. S. Food and Drug Administration (FDA) has given fast track status to AD109, an investigational oral medication for the treatment of obstructive sleep apnea, Apnimed announced in June. The FDA fast track is a process designed to facilitate the development of drugs that treat serious conditions and fill an unmet medical need and to expedite their review. AD109 contains the selective norepinephrine reuptake inhibitor atomoxetine and the selective antimuscarinic aroxybutynin.